Hence, FcγRIIB is a complex but promising target not only for tumor therapy but also for the treatment of autoimmune diseases like rheumatoid arthritis which could benefit from agonistic engagement and thus inhibitory signaling in autoreactive B cells [20, 21, 22]. This evidence concerns the gene FCGR2B and autoimmune disease.